Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors
Aurinia Pharmaceuticals has appointed Dr. Brinda Balakrishnan to its Board of Directors effective June 14, 2021. Dr. Balakrishnan currently serves as Group Vice President at BioMarin Pharmaceutical, where she oversees corporate strategy and business development. Her extensive background in biotech, particularly in rare diseases, is expected to enhance Aurinia's strategic direction and support its mission to treat autoimmune diseases like lupus nephritis. This move is seen as critical in positioning the company for future growth in the biopharmaceutical sector.
- Dr. Balakrishnan brings extensive experience in biotech and rare diseases.
- Her appointment is expected to strengthen corporate strategy and business development.
- Concerns about potential continuity and experience gaps in leadership.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) announced today the appointment of Dr. Brinda Balakrishnan, M.D., Ph.D., to the Company’s Board of Directors effective June 14, 2021. Dr. Balakrishnan is Group Vice President, Corporate and Business Development of BioMarin Pharmaceutical Inc. (“BioMarin”), a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare disorders. At BioMarin, Dr. Balakrishnan leads initiatives on corporate strategy, mergers and acquisitions, partnering and licensing.
Dr. Brinda Balakrishnan, newly appointed Director to the Aurinia Pharmaceuticals Board. (Photo: Business Wire)
“On behalf of the entire Company, it is an honor to welcome Dr. Balakrishnan to Aurinia’s Board of Directors,” commented Peter Greenleaf, President and Chief Executive Officer of Aurinia. “With her rich experience in medicine, biotech business development and the rare disease space, we are eager to leverage her input and insights as we continue in our mission to support and better treat people suffering with rare, autoimmune diseases, including lupus nephritis.”
“I am delighted to join the Board of Directors of Aurinia,” said Dr. Balakrishnan. “The Company is at an exciting moment in its evolution, and I look forward to working with the Board and management team as Aurinia continues on its mission to serve people suffering from debilitating autoimmune diseases.”
Dr. Balakrishnan has been at BioMarin since 2016. Prior to joining BioMarin, Dr. Balakrishnan was the co-founder and Vice President of corporate strategy and product development at Vision Medicines, Inc., a start-up focused on developing treatments for rare ophthalmic diseases. Before Vision Medicines, she spent two years as a consultant at McKinsey & Company in the healthcare practice, serving clients across small biotech, large pharma, and healthcare provider groups on topics related to corporate strategy, corporate and business development, and operations. Prior to McKinsey, Dr. Balakrishnan was in business development at Genzyme.
Dr. Balakrishnan earned a B.S. degree from the Massachusetts Institute of Technology (MIT) in chemical engineering and a Ph.D. from MIT in biomedical engineering and chemical engineering. She also earned her M.D. degree from Harvard Medical School and conducted her medical training in internal medicine at Beth Israel Deaconess Medical Center in Boston, a Harvard hospital.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210614005185/en/
FAQ
Who is Dr. Brinda Balakrishnan?
What role will Dr. Balakrishnan play at Aurinia?
When was Dr. Balakrishnan appointed to Aurinia's Board?
What is Aurinia's focus as a biopharmaceutical company?
How might Dr. Balakrishnan's appointment impact AUPH stock?
